These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 10979113)

  • 1. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA
    JAMA; 2000 Sep; 284(10):1263-70. PubMed ID: 10979113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
    Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
    Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
    Illingworth DR; Stein EA; Mitchel YB; Dujovne CA; Frost PH; Knopp RH; Tun P; Zupkis RV; Greguski RA
    Arch Intern Med; 1994 Jul; 154(14):1586-95. PubMed ID: 8031206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
    Brinton EA; Triscari J; Brudi P; Chen E; Johnson-Levonas AO; Sisk CM; Ruck RA; MacLean AA; Maccubbin D; Mitchel YB
    Lipids Health Dis; 2016 Jul; 15(1):116. PubMed ID: 27405296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
    Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC
    Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of extended-release niacin on lipoprotein subclass distribution.
    Morgan JM; Capuzzi DM; Baksh RI; Intenzo C; Carey CM; Reese D; Walker K
    Am J Cardiol; 2003 Jun; 91(12):1432-6. PubMed ID: 12804729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.